# The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)

> **NCT00292877** · PHASE2 · COMPLETED · sponsor: **St. Joseph's Healthcare Hamilton** · enrollment: 20 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** SB-240563 (Mepolizumab)

## Key facts

- **NCT ID:** NCT00292877
- **Lead sponsor:** St. Joseph's Healthcare Hamilton
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-07
- **Target enrollment:** 20 (—)
- **Last updated:** 2011-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00292877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00292877, "The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00292877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*